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Abstract: Besides its action on the nervous system, dopamine (DA) plays a role on neural-immune interactions. Here we 
review the current evidence on the dopaminergic system in human peripheral blood lymphocytes (PBL). PBL synthesize 
DA through the tyrosine-hydroxylase/DOPA-decarboxylase pathway, and express DA receptors and DA transporter 
(DAT) on their plasma membrane. Stimulation of DA receptors on PBL membrane contributes to modulate the develop-
ment and initiation of immune responses under physiological conditions and in immune system pathologies such as   
autoimmunity or immunodeficiency. 
The characterization of DA system in PBL gave rise to a further line of research investigating the feasibility of PBL as a 
cellular model for studying DA derangement in neuropsychiatric disorders. Several reports showed changes of the expres-
sion of DAT and/or DA receptors in PBL from patients suffering from several neuropsychiatric disorders, in particular 
parkinsonian syndromes, schizophrenia and drug- or alcohol-abuse. Despite some methodological and theoretical limita-
tions, these findings suggest that PBL may prove a cellular tool with which to identify the derangement of DA transmis-
sion in neuropsychiatric diseases, as well as to monitor the effects of pharmacological treatments. 
Keywords: Dopamine, dopamine receptors, dopamine transporter, neuropsychiatric disorders, peripheral blood lymphocytes. 
INTRODUCTION 
  The catecholamine, dopamine (DA), plays a cardinal role 
in the control of motor, cognitive, behavioral and endocrine 
functions in the central nervous system (CNS) [1]. DA cell 
bodies in the CNS are located within the substantia nigra 
pars compacta and ventral tegmental area in the mesencepha-
lon [2]. These neurons may be identified by the positive im-
munostaining for tyrosine-hydroxylase (TH) and DOPA-
decarboxylase [3]. The projecting axons reach the dorsal 
(nigrostriatal pathway) and ventral (mesolimbic pathway) 
striatum together with prefrontal cortical areas (mesocortical 
pathway), respectively [4]. A further DA pathway, defined as 
tuberoinfundibular, arises from cell bodies in the hypothala-
mus and reaches the anterior pituitary to inhibit prolactin 
secretion [5]. 
  The effects of DA in the CNS are mediated through acti-
vation of DA receptors. The amino acid sequence of each 
DA receptor subtype encodes the seven membrane-spanning 
regions characteristic of G protein-coupled receptors [1, 6]. 
Two distinct families of DA receptors have been identified, 
with opposite actions on adenylate cyclase [1, 7]: the D1-like 
receptors (D1 and D5 receptors) are coupled to a G protein 
that activates adenylate cyclase, whereas the D2-like recep-
tors (D2, D3 and D4 receptors) are negatively coupled to 
adenylate cyclase. Moreover, the diverse DA receptor sub-
types show different topographic segregation within the CNS  
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[1, 8]: thus, D1 receptors are abundant in the basal ganglia, 
nucleus accumbens and cerebral cortex, D2 receptors have 
highest concentrations in the basal ganglia and anterior pitui-
tary, D3 receptors in the ventral striatum (nucleus accum-
bens, islands of Calleja, olfactory tubercle), D4 receptors 
show highest density in the frontal cortex, hippocampus and 
amygdala, and D5 receptors are mainly located in the hippo-
campus and thalamus. 
  DA transmission in the CNS is regulated by the level of 
transmitter available for interactions with DA receptors. 
This, in turn, depends on the amount of DA released by ax-
onal firing and the rate of metabolism and re-uptake of the 
transmitter. DA metabolism occurs through two distinct, 
although partially interacting, pathways, the monoamine-
oxidase and the catechol-O-methyl-transferase [1, 9]. Under 
physiological conditions, DA re-uptake mostly depends on 
the presence and activity of DA transporter (DAT), a 80 kD 
glycoprotein belonging to the large Na
+/Cl
- dependent trans-
porter family, which includes norepinephrine, serotonin, 
GABA and glycine transporters. It consists of a 620-amino 
acid protein, organized in 12 transmembrane domains, with 
cytoplasmic amino- and carboxy-termini [10]. Intracellular 
DA levels available for synaptic transmission are also regu-
lated by the vesicular monoamine transporters (VMAT-1 and 
VMAT-2) that concentrate the DA into presynaptic vesicles 
[11]. 
  Neuroanatomical and/or functional derangement of   
of DA transmission in the CNS is a core feature of several 
neurological or psychiatric disorders. 
  The cardinal motor symptoms of Parkinson's disease 
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containing neurons in the substantia nigra pars compacta 
and, consequently, reduced extracellular DA concentrations 
in the striatum [12]. There is also evidence for damage of 
mesocorticolimbic DA neurons in PD [13]. Moreover, dam-
age of central DA neurons is commonly found in atypical 
parkinsonisms, including multiple system atrophy (MSA), 
progressive supranuclear palsy, Lewy bodies dementia and 
corticobasal degeneration [14], and may be observed in a 
discrete proportion of subjects suffering vascular or toxic 
parkinsonism [15]. Blockade of DA receptors is responsible 
for development of neuroleptic drug-induced parkinsonism 
[16]. Within movement disorders, finally, there is pharma-
cological [17] and neuroimaging [18] evidence for the patho-
logical involvement of DA transmission in Tourette's syn-
drome, a neuropsychiatric disorder characterized by multiple 
motor tics plus one or more vocal tics. 
  Alzheimer's disease (AD) is the most common cause of 
mental deterioration in elderly people. Neocortical deficit of 
choline acetyltransferase, reduction of choline uptake and 
acetylcholine release, as well as loss of cholinergic neurons 
from the nucleus basalis of Meynert, together with the estab-
lished role of acetylcholine in learning and memory, led to 
the cholinergic hypothesis of AD [19]. Other neurotransmit-
ter-receptor systems are, however, damaged in AD, includ-
ing catecholamines. In particular, loss of norepinephrine 
neurons in the locus coeruleus, degeneration of norepineph-
rine projections to the basal forebrain, and decreased cortical 
norepinephrine have been reported in AD [20]. Moreover, 
AD patients may show motor symptoms suggestive of patho-
logical involvement of the basal ganglia circuitries [12], and 
previous studies indicate the crucial role of corticostriatal 
dopaminergic networks in cognitive and motor processes in 
AD [21]. There is also evidence on the implication of DA in 
the development of delusions and apathy in AD [22]. 
  Following the first clinical and pharmacological sugges-
tions of altered DA transmission in migraineurs, studies on 
DA receptors have further emphasized the link between mi-
graine and DA, and suggested that DA receptors in mi-
graineurs have peculiar functional and genetic features, in-
cluding such as lowered activation threshold [23]. Further-
more, the positive association between allele 1 of D2 recep-
tors and the subgroup of migraineurs presenting both nausea 
and yawing, two known DA-related phenomena, immedi-
ately before or during the pain phase of migraine has been 
identified [24]. Finally, there is still debate on the possibility 
that a specific D2 receptor polymorphism might increase 
susceptibility to migraine with aura [25]. 
  Schizophrenia is one of the most common mental disor-
ders, but its etiology and pathophysiology are still obscure. 
Several studies have suggested changes in DA systems in 
schizophrenia. However, the dopaminergic hypothesis for 
schizophrenia is still largely based on the consequences of 
pharmacologic manipulations of DA transmission either by 
mimicking [26] or reducing [27] the symptoms of schizo-
phrenia. With this respect, one should consider that func-
tional changes of DA systems may occur as the consequence 
of DA itself as well as DA receptors. 
  Stimulation of mesolimbic DA transmission is a common 
consequence of the administration of drugs of abuse belong-
ing to different pharmacological classes to experimental 
animals [28-30] as well as humans [31]. Mesolimbic DA 
transmission is thought to play a fundamental role for the 
rewarding properties of these drugs, as well as for the acqui-
sition and maintenance of associative learning processes 
related to drug addiction and relapse [32]. 
  Finally, DA transmission in the CNS has been implicated 
in some behavioral features of depression. The strongest 
evidence implicating DA involvement in depression derived 
from the observation of lower homovanillic acid concentra-
tions in the cerebrospinal fluid from depressed patients [33, 
34]. In particular, the anhedonic symptoms frequently en-
countered in depressed subjects have been related to altered 
mesolimbic DA transmission [35] and may be ameliorated 
by dopaminergic therapies [36]. Conversely, DA receptor 
antagonists may aggravate depression-like symptoms [35]. 
  Besides of its action on the nervous system, DA has been 
identified in other organs and tissues, including the vascular 
beds, the hearth, the gastrointestinal tract, and the kidney. 
Moreover, a number of studies showed DA components in 
the immune system, and suggested that DA plays a key role 
on neural-immune interactions and immune cells in particu-
lar. Here we review these articles with the aim to provide an 
up-to-date definition of the DA system in peripheral blood 
lymphocytes (PBL), as well as to support the feasibility of 
PBL as a cellular tool with which to investigate DA de-
rangement in neuropsychiatric disorders. For our purpose, 
the database was selected using PubMed Services including 
the following keywords: dopamine, dopamine receptors, 
dopamine transporter, peripheral blood lymphocytes. In ad-
dition, the bibliographies of all relevant articles were 
searched for further publications. The articles were restricted 
to English language and spanned the period from January 
1980 to February 2010. Historically remarkable or conceptu-
ally related articles were included as well. All articles cited 
in this manuscript were judged by F.R.B. and F.E.P. to be 
relevant and to meet the scientific and conceptual criteria 
listed. 
THE DOPAMINERGIC SYSTEM IN PERIPHERAL 
BLOOD LYMPHOCYTES 
  The original discovery of endogenous DA in PBL was 
made by Bergquist et al. [37] back in 1994 (Table 1). The 
authors applied capillary electrophoresis with electrochemi-
cal detection to quantify DA and its metabolites in single 
lymphocytes and extracts of T- and B-cell clones. Moreover, 
pharmacological inhibition of TH by  -methyl-p-tyrosine 
reduced observed catecholamine levels, suggesting direct 
synthesis of catecholamines by PBL, and intracellular DA 
levels were increased by exposure to extracellular DA, sug-
gesting the presence of an active cellular uptake mechanism. 
Four years later [38], the same research group confirmed the 
presence of DA, L-DOPA, and norepinephrine in PBL by 
electrospray ionization mass spectroscopy. In 1996, Musso et
al. [39] studied catecholamine content in human PBL and the 
ability of these cells to synthesize catecholamines in vitro.
Catecholamines were separated by high performance liquid 
chromatography (HPLC) and electrochemical detection. T-
lymphocytes contained L-DOPA and norepinephrine, 
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able to synthesize norepinephrine from both L-tyrosine and 
L-DOPA added to the incubation medium, thus indicating 
the presence of active synthetic pathways. In 2004, Qiu et al.
[40] confirmed that human PBL may synthesize catechola-
mines, including DA, by combining immunochemical meth-
ods to investigate the expression of TH, HPLC to measure 
catecholamine content, and western blot to examine and 
quantify TH-stained protein. Moreover, Cosentino et al. [41] 
showed that human T-lymphocytes constitutively express 
TH, the rate-limiting enzyme in the synthesis of catechola-
mines, and contain substantial amounts of DA, epinephrine 
and norepinephrine, which may be released upon treatment 
with reserpine. Finally, Kikkonou et al. [42] reported in   
2007 the expression of the gene coding for L-DOPA-
decarboxylase in human PBL. 
  Despite such converging evidence for the presence of 
catecholamines, and DA in particular, in PBL, early research 
on the characterization of DA receptors gave rather contra-
dictory results. Studies by Maloteaux et al. [43], Fleminger 
et al. [44], Feenstra et al. [45], and Coccini et al. [46] ques-
tioned the presence of DA receptors in PBL. Indeed, these 
authors showed that haloperidol displaceable component of 
[
3H]-spiperone binding to human PBL was not saturable, and 
that stereoselective displacement by the isomers of buta-
clamol was not observed. Also, there was no correlation be-
tween the ability of known DA active drugs to cause dis-
placement of the ligand and their rank order of potency, thus 
suggesting that the apparent association of [
3H]-spiperone 
with PBL might be due to some passive uptake process caus-
ing accumulation of the ligand within the cells. As discussed 
by Wodarz et al. [47], however, methodological biases (un-
specific filter binding, which increased the presence of buta-
clamol, or variable amount of contaminating granulocytes) 
might have contributed to these negative results. 
  In 1991, Faraj et al. [48] (Table 1) first reported the oc-
currence of binding to DA receptors in PBL, markedly af-
fected by cocaine and other inhibitors of biogenic amine 
uptake. One year later, Takahashi et al. [49] applied sequen-
tial reverse transcription and polymerase chain reaction (RT-
PCR) to demonstrate the presence of three types of mRNA 
sequences, each corresponding to those of the D5 receptor 
gene and the two related pseudogenes, in human PBL. The 
PBL cDNA library also contained the clones encoding parts 
of the three genes. Binding profiles of dopaminergic ligands 
Table 1.  The Dopaminergic System in Peripheral Blood Lymphocytes. The Table Summarizes the Methodology Applied and the 
Findings Obtained. DA=Dopamine, DAT=Dopamine Transporter, VMAT-1, 2= Vesicular Monoamine Transporters 
Authors Methology  Finding 
Bergquist et al. [37]  Capillary electrophoresis  DA and DA metabolites 
Bergquist and Silberring [38]  Mass spectroscopy  DA, L-DOPA, norepinephrine 
Musso et al. [39]  HPLC with electrochemical detection  L-DOPA and norepinephrine 
Qiu et al. [40]  Immunochemistry, HPLC, Western blot  Tyrosine hydroxylase, DA, L-DOPA, norepinephrine 
Kikkonou et al. [42]  RT-PCR  L-DOPA decarboxylase gene 
Faraj et al. [48]  Receptor binding assay  DA receptors 
Takahashi et al. [49] RT-PCR  D5  receptor  gene 
Nagai et al. [50] RT-PCR  D3  receptor  gene 
Santambrogio et al. [51]  Receptor binding assay  D2, D4 receptors 
Ricci and Amenta [52]  Receptor binding assay  D5 receptor 
Ricci et al. [53]  Receptor binding assay  D3 receptor 
Bondy et al. [55]  RT-PCR  D4 receptor gene 
Ricci et al. [56]  Receptor binding assay  D4 receptor 
Ricci et al. [57]  Receptor binding assay, immunochemistry  D3, D4 receptors 
Ricci et al. [58]  Receptor binding assay  D5 receptor 
McKenna et al. [59]  Flow cytometry  D2, D3, D4, D5 receptors 
Kirillova et al. [60]  Receptor binding assay, RT-PCR  D5 receptor 
Amenta et al. [61]  Receptor binding assay, Western blot  DAT, VMAT-1, VMAT-2 
Marazziti et al. [62]  Receptor binding assay  DAT Dopaminergic System in PBL  Current Neuropharmacology, 2011, Vol. 9, No. 2    281
to the PBL were similar to those for the native neuronal 
membranes. Using the same methodologies, Nagai et al. [50] 
reported in 1993 the occurrence of a novel shorter variant 
transcript of the D3 receptor gene generated by alternative 
splicing in PBL and brain. Receptor binding studies by San-
tambrogio et al. [51] further contributed to characterize DA 
receptors in PBL by showing high affinity, specific, satur-
able and reversible binding of [
3H]-sulpiride to human PBL. 
In this latter study, the pharmacological characterization of 
the binding sites suggested the presence of D2 and D4 recep-
tor subtypes in PBL. In 1994, Ricci and Amenta [52] de-
scribed the occurrence of D1-like receptors in human PBL 
by means of radioligand binding technique. In that study, 
binding to [
3H]-SCH23390 was applied to localize D1-like 
receptors. Pharmacological analysis of displacement curves 
of radioligand with DA competing with the radioligand in 
submicromolar range suggested the presence of D5 rather 
than D1 receptors. Using the same technique, these authors 
also reported the occurrence of high-affinity [
3H]-OH-DPAT 
binding to D3 receptors in human PBL [53]. Interestingly, 
binding was time-, temperature-, and concentration-
dependent, and it was also reversible. The rank order of po-
tency of displacers was similar to those found for D3 recep-
tors in rat brain homogenates or in rat or human cell lines. 
The same research group also showed age-dependent reduc-
tion of DA receptor subtypes in human PBL [54]. In 1996, 
Bondy et al. [55] applied RT-PCR to demonstrate the ex-
pression of D4 receptors in human PBL. Receptor binding 
evidence of the expression of this latter subtype of DA re-
ceptor was provided the following year by Ricci et al. [56]. 
In 1997, this latter group [57] defined more precisely the 
occurrence of D3 and D4 receptors by combining receptor 
binding assay and immunocytochemistry for D2-like recep-
tor subtypes. Within D1-like receptor subtypes, the authors 
confirmed that only D5 receptors were expressed on PBL 
membrane [58]. Finally, in 2002, McKenna et al. [59] con-
firmed that D5 receptors were the only D1-like receptors 
expressed in PBL, whereas all D2-like receptor subtypes 
(D2, D3, and D4) were expressed. The specificity of expres-
sion of D5 receptors was further confirmed by Kirillova et
al. [60]. 
  The first report of the presence of DAT on human PBL 
membrane came by Amenta et al. in 2001 [61] (Table 1). In 
that paper, the authors demonstrated specific binding of [
3H]-
GBR12935 to PBL, with a dissociation constant similar to 
that found in the striatum, but with lower density of binding 
sites. Moreover, western blot analysis using antibodies raised 
against amino- or carboxy-termini of DAT or against 
VMAT-1 and VMAT-2 revealed labeling of single bands of 
approximately 76, 55 or 68 kD, respectively, displaying 
similar migration characteristics in PBL and test tissues used 
for comparisons. Immunofluorescence revealed that anti-DA, 
anti-TH, anti-DAT, anti-VMAT-1 and anti-VMAT-2 anti-
bodies labeled the total population of cytospin-centrifugated 
PBL mounted on microscope slides. Confocal laser micros-
copy demonstrated that DA and VMAT-2 immunoreactivity 
was present mainly in cytoplasmic puntiform areas, that were 
likely to correspond to vesicles, and to a lower extent was 
associated to plasma membrane. TH immunoreactivity was 
diffused to cytoplasm and to plasma membrane of PBL, 
whereas DAT and VMAT-1 immunoreactivities were lo-
cated almost exclusively in PBL plasma membrane and   
cytoplasm, respectively. Finally, in 2008, Marazziti et al.
[62] showed the presence of specific and saturable binding of 
[
3H]-WIN35, 428, a very selective DAT binding compound, 
together with specific [
3H]-DA re-uptake by human PBL. 
PHYSIOLOGY AND PHARMACOLOGY OF DA   
SYSTEM IN IMMUNE CELLS 
  By stimulating DA receptors expressed on PBL mem-
brane, DA from diverse sources (plasma, sympathetic nerv-
ous system, autocrine or paracrine secretion by immune 
cells, CNS) may contribute to regulate the initiation and de-
velopment of immune responses.  
  Studies carried out on human and murine T-cells have 
shown that stimulation of D1-like receptors impairs T-cell 
function by causing the rise of intracellular cAMP levels. 
Further evidence indicates that stimulation of D1-like recep-
tors not only inhibits cytotoxic function of CD8
+ T-cells [63] 
but also impairs function and differentiation of T-regulatory 
cells (Tregs) [41, 64]. Moreover, stimulation of D1-like re-
ceptors has been involved in the polarization of naïve CD4
+
T-cells toward Th17 cells [65, 66]. Because Th17 and Tregs 
cells are involved in autoimmunity as auto-aggressive and 
beneficial cells respectively, it is likely that D1-like receptors 
expressed on T-cells are involved in the interface between 
autoimmunity and health. Interestingly, the decreased ex-
pression of D5 receptors in PBL has been found in patients 
suffering multiple sclerosis [67]. 
  D2-like receptors are also involved in the modulation of 
T-cells physiology. For instance, it has been demonstrated 
that stimulation of these latter receptors promotes enhanced 
production of interleukin-10, a cytokine that negatively regu-
lates the function of effector T-cells [68]. This inhibition 
could be involved in the polarization toward Tregs. Regard-
ing D4 receptor stimulation, evidence indicates that this re-
ceptor triggers T-cell quiescence by up-regulating Krüppel-
like factor-2 (KLF-2) expression [69, 70]. On the other hand, 
whereas D3-stimulation facilitates differentiation of naïve 
CD8
+ T-cells into CTLs [68], it also contributes to polariza-
tion of naïve CD4
+ T-cells toward Th1 effector phenotype 
[71]. Furthermore, stimulation via D3 receptor is thought to 
be involved in migration and adhesion of T-cells, thus modu-
lating the homing of these cells [71-73]. 
CHANGES OF PBL DA SYSTEM IN NEUROLOGI-
CAL DISEASES 
  Following the initial characterization of the DA system in 
human PBL, the question raised of whether PBL may repre-
sent a useful cellular model with which to investigate the 
derangement of DA transmission in patients suffering neuro-
logical or psychiatric disorders. 
  Because of the prominent role of DA derangement in 
parkinsonian syndromes, most studies were centered on 
these disorders (Table 2). Early research by Le Fur et al. [74] 
showed the dramatic decrease of the number of [
3H]-
spiroperidol binding sites in PBL from untreated PD patients 
with respect to controls and patients suffering other neuro-
logical disorders. This decrease was linearly correlated with 
the degree of disability of PD patients, and was rescued by 
L-DOPA therapy. However, in 1983, Maloteaux et al. [75] 282    Current Neuropharmacology, 2011, Vol. 9, No. 2 Buttarelli et al. 
questioned these results by showing that [
3H]-spiperone 
binding to PBL did not reveal the occurrence of DA recep-
tors, although lower values were observed in PD patients and 
the displaceable binding was increased after L-DOPA treat-
ment, suggesting that the non specific binding was due to 
trapping presumably in lysosomes. Following these results, 
the polish group headed by Czlonkowski showed the de-
crease of [
3H]-spiroperidol binding to PBL from patients 
suffering Wilson's disease as compared to blood donors [76, 
77]. In 1993, Nagai and collaborators [78] investigated DA 
receptor mRNAs expression in PBL from 45 PD patients and 
21 age-matched controls using RT-PCR method with -actin 
as internal control and DA receptor binding. The authors 
found the statistically significant decrease of the D3 receptor 
mRNA expression in PBL from PD patients, that correlated 
with disease severity. Moreover, there was also a decrease of 
D3 receptor binding sites in PBL from PD patients with re-
spect to controls. Conversely, no change of D5 receptor 
mRNA expression was detected. Finally, in 1999, Barbanti et
al. [79] applied receptor binding methods to investigate the 
changes of D1-like and D2-like receptor sites in PBL from 
50 de novo PD patients, 36 neurological control subjects 
(patients suffering essential tremor, MSA and other neurode-
generative diseases) and 26 healthy subjects. In this study, 
PBL from PD patients showed a higher density of both D1-
like and D2-like binding sites that either neurological or 
healthy control subjects. The pharmacological profile of 
[
3H]-SCH23390 and [
3H]-7OH-DPAT binding was consis-
tent with labeling of D5 and D3 receptor subtypes, respec-
tively. In a subgroup of PD patients, the density of D1-like 
and D2-like binding sites lowered to values comparable to 
controls after 3-month therapy with L-DOPA or bro-
mocriptine. The authors suggested that the increased density 
of D1-like and D2-like receptor on PBL in de novo PD pa-
tients may represent an up-regulation mechanism resulting 
from diffuse impairment of DA systems in PD. 
  Our research group contributed a number of articles on 
the alterations of DA system in PBL from PD patients. Early 
studies showed the reduction of intracellular DA concentra-
tions and TH immunoreactivity in PBL from PD patients 
with respect to healthy subjects [80]. Immunocytochemical 
methods with semi-quantitative computer-assisted densi-
tometry was also applied to identify the reduction of DAT 
immunoreactivity in PBL from de novo PD patients with 
respect to healthy controls [81] and patients suffering essen-
tial tremor [82], a neurological disorder clinically character-
ized by postural tremor with slight signs of rigidity that is 
not accompanied by central DA damage. Despite the reduced 
expression of DAT on PBL plasma membrane in PD pa-
tients, intracellular concentrations of DA were significantly 
increased by L-DOPA therapy [80, 83], indicating the effi-
ciency of DA re-uptake mechanisms. Finally, in a recent 
study, we combined immunocytochemistry for DAT on PBL 
and [
123I]-fluopane binding to the striatum to investigate the 
possible correlation between central and peripheral DAT 
levels in a group of de novo PD patients [84]. The results of 
this latter study showed the lack of significant correlation 
between PBL and striatal DAT levels. Moreover, there was 
no correlation between central and peripheral DAT expres-
sion in patients suffering essential tremor, whereas there was 
a highly significant correlation between PBL and striatal 
DAT expression in PD patients treated with dopaminergic 
therapy (L-DOPA and/or dopamine agonists) [85]. 
  Further studies showed the reduction of DAT immuno- 
reactivity in PBL also in subjects suffering MSA [86]   
(Table 3); in these patients, a slight, not significant, increase 
of DAT immunoreactivity in PBL was measured following 
withdrawal from L-DOPA therapy [86]. Finally, the reduc-
tion of DAT immunoreactivity was measured also in a sub-
population of subjects suffering amyotrophic lateral sclerosis 
[87] (Table 3). With respect to this latter disease, it is   
relevant to note that pathological [88] and neuroimaging   
[89] studies showed the partial damage of nigrostriatal DA 
system. 
  As to other neurodegenerative diseases (Table 3), Ferrari 
et al. [90] reported recently the increase of D5 receptor 
mRNA levels in PBL from patients suffering Tourette's syn-
drome with respect to healthy subjects. In this study, D5 
mRNA expression in PBL showed a highly positive correla-
Table 2.  Changes of Dopaminergic Markers in Peripheral Blood Lymphocytes in Parkinson's Disease. The Table Summarizes the 
Methodology Applied and the Findings Obtained. DA=Dopamine, DAT=Dopamine Transporter 
Authors Methodology  Findings 
Le Fur et al. [74]  Receptor binding assay  Decreased D2-like receptor 
Nagai et al. [78]  RT-PCR and Receptor binding assay  Decreased D3 receptor 
Barbanti et al. [79]  Receptor binding assay  Increased D3 and D5 receptors 
Caronti et al. [80]  Immunochemistry, HPLC with  
electrochemical detection 
Decreased TH immunoreativity,  
Decreased intracellular DA concentration 
Caronti et al. [81]  Immunochemistry  Decreased DAT immunoreactivity 
Pellicano et al. [82]  Immunochemistry  Decreased DAT immunoreactivity 
Buttarelli et al. [84]  Immunochemistry  Decreased DAT immunoreactivity 
Pontieri and Colosimo [85]  Immunochemistry  Decreased DAT immunoreactivity Dopaminergic System in PBL  Current Neuropharmacology, 2011, Vol. 9, No. 2    283
tion with the severity of compulsive symptoms. There is also 
initial evidence of the possibility to detect derangement of 
catecholaminergic systems in PBL from subjects suffering 
AD. PBL from AD patients showed reduced density of   
D2-like receptors [91], and increased DOPA-decarboxylase 
immunoreactivity [92] with respect to those from healthy 
controls. 
  Besides of neurodegenerative disorders, the increased 
density of D3, D4, and D5 receptor binding sites on PBL 
from patients suffering migraine with respect to healthy   
subjects has been reported [93, 94] (Table 3). The authors 
suggested that this receptor up-regulation might represent a 
peripheral adaptative response to central DA alterations. 
CHANGES OF PBL DA SYSTEM IN PSYCHIATRIC 
DISEASES 
  Studies on the alterations of DA system in PBL from 
schizophrenic patients (Table 4) were pointed mostly on the 
changes of expression of DA receptors. In 1985, Bondy et al.
[95] reported that specific binding of [
3H]-spiperone was 
significantly increased in PBL from unmedicated schizo-
phrenic patients with respect to healthy subjects or unmedi-
cated psychiatric control subjects. However, the author's 
suggestion of the possibility to apply such method as a vul-
nerability marker was denied by Griffiths et al. [96]. In 2001, 
Kwak et al. [97] applied RT-PCR to investigate the expres-
sion of DA receptors in PBL from medicated and unmedi-
cated schizophrenic patients and healthy subjects. D3 recep-
tor mRNA was significantly increased in PBL from unmedi-
cated schizophrenic patients as compared to values in medi-
cated patients and healthy subjects. Conversely, D5 receptor 
mRNA expression in PBL from unmedicated schizophrenic 
patients was significantly higher than medicated ones but not 
healthy subjects. In drug naïve or drug free patients, mRNA 
for DA receptors peaked after 2 weeks of treatment with 
antipsychotics, and decreased to levels still above baseline at 
8
th week of treatment. Moreover, drug naïve and drug free 
patients were divided into two groups according to DA re-
ceptor expression before medication, and the group of pa-
tients with increased DA receptor mRNA expression had 
more severe psychiatric symptoms. In the same year, Ilani et
al. [98] demonstrated the significant (2- to 7-fold) increase 
of D3 but not D4 receptor mRNA in PBL from unmedicated 
schizophrenic patients with respect to healthy subjects. This 
increase was not affected by treatment with typical or atypi-
cal antipsychotic drugs. In 2003, Singh et al. [99] reported 
that the positive antipsychotic effects of loxapine, a mid-
potency typical neuroleptic, was associated with reduced D2-
like receptor binding in PBL. Finally, in 2006, Boneberg et 
al. [100] investigated the expression of DA receptors in puri-
fied human neutrophils, monocytes, B cells, natural killer 
cells and CD4
+- and CD8
+-positive T cells by RT-PCR. The 
results showed the significant increase of D3 receptor 
mRNA in T cells and the significant decrease of D4 receptor 
mRNA expression in CD4
+-T cells from schizophrenic pa-
tients with respect to healthy subjects. In contrast with these 
reports, Vogel et al. [101] in 2004 reported the reduction of 
D3 receptor mRNA expression in PBL from schizophrenic 
and bipolar patients. In this study, antipsychotic treatment in 
schizophrenic patients produced significant increases of D3
receptor mRNA expression. Finally, a recent study by 
Marazziti et al. [102] demonstrated the reduction of DAT 
expression in PBL from psychotic patients with respect to 
healthy subjects. 
 Biermann  et al. [103] investigated recently the changes 
of DA receptor expression in PBL during alcohol withdrawal 
(Table 5). The increase of D1 receptor expression reached 
significance in the early phase of withdrawal, whereas a not-
significant increase of D2 receptor expression was observed 
throughout all withdrawal period. Czermak et al. [104] re-
ported the reduction of D4 receptor mRNA expression in 
PBL of long-term abstinent alcohol and heroin addicts, thus 
suggesting a withdrawal-persisting DA imbalance in absti-
nent addicts as measured by a suggested peripheral marker. 
Similarly, Goodarzi et al. [105] showed the increase of D3 
receptor mRNA expression in PBL from heroin-addicted and 
Table  3.  Changes of Dopaminergic Markers in Peripheral Blood Lymphocytes in other Neurological Disorders. The Table   
Summarizes the Methodology Applied and the Findings Obtained. DA=Dopamine, DAT=Dopamine Transporter, 
DBH=Dopamine-Beta-Hydroxylase 
Authors Methodology  Disease  Findings 
Czlonkowski et al. [76]  Receptor binding assay  Wilson's disease  Decreased D2-like receptor 
  Receptor binding assay  Wilson's disease  Decreased D2-like binding 
Buttarelli et al. [86]  Immunochemistry  Multiple system atrophy  Decreased DAT immunoreactivity 
Buttarelli et al. [87]  Immunochemistry  Amyotrophic lateral sclerosis  Decreased DAT immunoreactivity 
Ferrari et al. [90]  Receptor binding assay  Tourette's syndrome  Increased D5 receptor 
Barbanti et al. [91]  Receptor binding assay  Alzheimer's disease  Decreased D2-like receptors 
Giubilei et al. [92]  Immunochemistry  Alzheimer's disease  Increased DBH immunoreactivity 
Barbanti et al. [93]  Receptor binding assay  Migraine  Increased D5 receptors 
Barbanti et al. [94]  Receptor binding assay  Migraine  Increased D3, D4 receptors 284    Current Neuropharmacology, 2011, Vol. 9, No. 2 Buttarelli et al. 
methadone-maintained subjects, the decrease of D4 mRNA 
expression in PBL from heroin-abstinent and heroin-addicted 
subjects, and the reduction of D5 mRNA expression in her-
oin-abstinent subjects solely. 
  As to studies on depression (Table 5), Rocca et al. [106] 
reported the significant reduction of D4 receptor mRNA in 
PBL from untreated patients suffering major depression. 
Such changes were reversed following therapy with paroxet-
ine. The reduction of serotonin, but not DA, turnover in PBL 
from depressed patients was reported by Fajardo et al. [107]. 
CONCLUSIONS AND FUTURE PERSPECTIVES 
  The studies reviewed herein contributed to characterize 
the dopaminergic system in PBL and to clarify the physio-
logical role of DA on PBL function. Further insight into DA-
mediated regulation of immune function is critical to under-
standing its role in unbalanced immune responses, including 
autoimmunity, immunodeficiency or tumor growth. 
  The relevant involvement of DA-mediated regulation of 
immune response is evidenced by deregulation of DA recep-
tors expressed on T-cells and alterations of plasma DA lev-
els, both conditions found as part of the pathophysiological 
scenario in some immune-related and neurological disorders. 
In this regard, deregulation of DA receptors expression and 
plasma DA levels follow a trend geared toward exacerbate 
the imbalance of immune response. For instance, plasma DA 
levels, which in general inhibit T-cell function, are increased 
in malignancies [108], but decreased in autoimmune disor-
ders [67, 109]. The precise knowledge of deregulation of 
plasma DA concentration and DA receptors expression on T-
cells under different pathophysiological conditions, together 
with an understanding of the precise role of stimulation of 
each DA receptor subtype on T-cell physiology could facili-
tate to the design of therapies for the treatment of autoimmu-
nity, immunodeficiency and cancer. 
  A further line of research reviewed in the present article 
dealt with the feasibility of PBL as a cellular model for in-
vestigating the alterations of DA system in neuropsychiatric 
disorders, in particular parkinsonian syndromes and schizo-
phrenia. 
  With respect to PD (Table 2), the results from a number 
of studies demonstrated that PBL may, indeed, represent a 
tool with which to identify alterations of DA system in vivo.
Thus, there is evidence for the reduction of intracellular DA 
content [80], the reduction of TH [80] and DAT [81, 82, 84] 
immunoreactivities, as well as changes of the expression of 
DA receptors [78, 79] in PBL from de novo PD patients. 
Such alterations contributed to the definition of the altera-
tions of DA systems outside the brain in the disease [85]. 
Moreover, the observation that therapy with L-DOPA or DA 
agonists may reverse the original alterations of the expres-
sion of DA receptors [79] suggested that PBL may serve as a 
cellular tool to investigate in vivo the adaptative changes of 
DA receptors to pharmacological treatments. 
  The current evidence of reduction of DA markers, and 
DAT immunoreactivity in particular, in PBL from subjects 
Table  4.  Changes of Dopaminergic Markers in Peripheral Blood Lymphocytes in Schizophrenia. The Table Summarizes the   
Methodology Applied and the Findings Obtained. DAT=Dopamine Transporter 
Authors Methodology  Findings 
Bondy et al. [95]  Receptor binding assay  Increased D2-like binding 
Kwak et al. [97]  RT-PCR  Increased D3 receptor mRNA 
Ilani et al. [98]  RT-PCR  Increased D3 receptor mRNA 
Boneberg et al. [100]  RT-PCR  Increased D3 receptor mRNA Decreased D4 receptor mRNA 
Vogel et al. [101]  RT-PCR  Reduced D3 receptor mRNA 
Marazziti et al. [102]  Receptor binding assay  Reduced DAT binding 
Table 5.  Changes of Dopaminergic Markers in Peripheral Blood lymphocytes in other Psychiatric Disorders. The Table Summa-
rizes the Methodology Applied and the Findings Obtained 
Authors Methodology Disease  Findings 
Biermann et al. [103]  RT-PCR  Alcohol withdrawal  Increased D1 receptor mRNA 
Czermak et al. [104]  RT-PCR  Alcohol- and heroin withdrawal  Reduced D4 receptor mRNA 
Goodarzi et al. [105]  RT-PCR  Heroin addiction Heroin abstinence  Increased D3 receptor mRNA Decreased D5 receptor mRNA 
Rocca et al. [106]  RT-PCR  Depression  Reduced D4 receptor mRNA 
Fajardo et al. [107]  HPLC  Depression  Reduced intracellular serotonin concentration Dopaminergic System in PBL  Current Neuropharmacology, 2011, Vol. 9, No. 2    285
suffering neurodegenerative disorders (PD, MSA, ALS) [81, 
82, 84, 86, 87] (Table 3), and the observation that such re-
ductions may be measured already in the early stages of 
these disorders, suggested that alterations of PBL DA system 
may be identified precociously in these diseases and might, 
theoretically, contribute to the identification of subjects at 
risk. Despite such suggestions, the results of recent studies 
from our group [82, 85, 86] showed the inability for DAT 
expression in PBL to discriminate between different neu-
rodegenerative disorders involving the central DA systems, 
and, consequently, the lack of validation of these measure-
ments for the differential diagnosis among these conditions. 
Moreover, the lack of correlation between striatal and PBL 
DAT expression in de novo PD patients [84] suggested that 
different mechanisms of regulation of DAT expression occur 
at central and peripheral level, at least under pathological 
conditions involving DA-containing cells. 
  As to other neurodegenerative disorders, changes of DA 
markers in PBL were measured in Wilson's disease [76], 
Tourette's syndrome [90], and AD [91] (Table 3). In particu-
lar, the observation of reduced density of D2 receptors in 
PBL from AD patients [91] suggests to further investigate 
the possible association between changes of DA receptor 
density and clinical symptoms such as apathy in the disease.  
  As to psychiatric disorders, there is consistent evidence 
of the possibility to identify changes of the expression of 
different DA receptor subtypes in PBL from schizophrenic 
patients [95, 97-101] (Table 4). In most cases, up-regulation 
of the expression of D3 receptors was found, suggesting the 
increased functional response to DA stimulation. Interest-
ingly, these changes appeared to correlate with the severity 
of psychiatric symptoms [97], and were at least partially 
modulated by antipsychotic drugs [97, 101]. Thus, these re-
sults indicate that PBL may, indeed, represent a useful tool 
with which to monitor the changes of DA receptor expres-
sion with respect to the efficacy of therapeutic interventions. 
Similarly, dynamic changes of DA receptor subtypes were 
measured during drug- or alcohol-withdrawal [103-105] 
(Table 5). These latter data indirectly confirm the role of DA 
transmission in the process of drug addiction. Finally, the 
observations of reduced D4 receptor expression in PBL from 
depressed patients (Table 5) gave further support to the 
pathogenetic role of DA transmission in depression. 
  Taken together, therefore, the results from a number of 
studies support the hypothesis that PBL may represent a use-
ful tool for investigating the changes of DA system in CNS 
pathologies, as well as to monitor with the consequences of 
pharmacological manipulations of DA transmission. This is, 
to our opinion, particularly relevant in view of the economi-
cal and technical difficulties of investigating such changes 
directly in the CNS in vivo. However, some limitations to the 
use of PBL as 'surrogate' markers for studying the changes of 
DA system in neuropsychiatric diseases should be acknowl-
edged, in particular the observation that these cells are sur-
rounded by different environments and, therefore, subjected 
to different mechanisms of regulation [110]. In any case, the 
ease and relative safety of obtaining blood cells have pro-
moted  in vivo studies and provided intriguing information 
that continues to receive further support. 
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